GlassScriptPhysician profile
Amber D King
NPI 1316472392
$1,078.04
in general payments reported to CMS, 2019-2025
11 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $71.88 · 2023: $275 · 2024: $263 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.27 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $291.12 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Astellas Pharma US INC | $179.25 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $155.88 | 2023-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Novo Nordisk INC | $129.95 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $119.28 | 2023-2025 | |
| Exact Sciences Corporation | $51.13 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $50.90 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.78 | 2024-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $23.23 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $22.71 | 2024 | |
| Glaxosmithkline, LLC. | $15.81 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.